請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/17260
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 沈麗娟(Li-Jiuan Shen) | |
dc.contributor.author | Guan-Lin Chen | en |
dc.contributor.author | 陳冠霖 | zh_TW |
dc.date.accessioned | 2021-06-08T00:03:36Z | - |
dc.date.copyright | 2013-09-24 | |
dc.date.issued | 2013 | |
dc.date.submitted | 2013-08-14 | |
dc.identifier.citation | 1. Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Annals of internal medicine 2002;137:947-54.
2. FDA Expands Advice on Statin Risks. 2012. at http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm293330.htm) 3. Navarro VJ, Senior JR. Drug-related hepatotoxicity. The New England journal of medicine 2006;354:731-9. 4. Navarro V. Hepatic adverse event nomenclature document [on line]. Avaliable from: http://www.fda.gov/downloads/Drugs/ScienceResearch/ResearchAreas/ucm080365.ppt 5. Reuben A, Koch DG, Lee WM. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010;52:2065-76. 6. Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002;36:451-5. 7. de Abajo FJ, Montero D, Madurga M, Garcia Rodriguez LA. Acute and clinically relevant drug-induced liver injury: a population based case-control study. British journal of clinical pharmacology 2004;58:71-80. 8. Andrade RJ, Lucena MI, Fernandez MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005;129:512-21. 9. Bjornsson ES, Bergmann OM, Bjornsson HK, Kvaran RB, Olafsson S. Incidence, Presentation, and Outcomes in Patients With Drug-Induced Liver Injury in the General Population of Iceland. Gastroenterology 2013;144:1419-25 e3. 10. De Valle MB, Av Klinteberg V, Alem N, Olsson R, Bjornsson E. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Alimentary pharmacology & therapeutics 2006;24:1187-95. 11. Sistanizad M, Peterson GM. Drug-induced liver injury in the Australian setting. Journal of clinical pharmacy and therapeutics 2013;38:115-20. 12. Zhou Y, Yang L, Liao Z, He X, Zhou Y, Guo H. Epidemiology of drug-induced liver injury in China: a systematic analysis of the Chinese literature including 21 789 patients. European journal of gastroenterology & hepatology 2013;25:825-9. 13. 趙必暉, 陳文雯, 翁菀菲. 藥品引起肝傷害:國內藥物不良反應通報資料分析. 臺灣醫學 2013;17. 14. Fountain FF, Tolley E, Chrisman CR, Self TH. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest 2005;128:116-23. 15. Chalasani N, Bjornsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology 2010;138:2246-59. 16. Bell L, Chalasani N. Epidemiology of Idiosyncratic Drug-Induced Liver Injury. Seminars in Liver Disease 2009;29:337-47. 17. Shapiro MA, Lewis JH. Causality assessment of drug-induced hepatotoxicity: promises and pitfalls. Clinics in liver disease 2007;11:477-505, v. 18. Lucena MI, Andrade RJ, Kaplowitz N, et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology 2009;49:2001-9. 19. Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2004;10:1018-23. 20. Kwon YS, Koh WJ, Suh GY, Chung MP, Kim H, Kwon OJ. Hepatitis C virus infection and hepatotoxicity during antituberculosis chemotherapy. Chest 2007;131:803-8. 21. Wu JC, Lee SD, Yeh PF, et al. Isoniazid-rifampin-induced hepatitis in hepatitis B carriers. Gastroenterology 1990;98:502-4. 22. Wong WM, Wu PC, Yuen MF, et al. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 2000;31:201-6. 23. Riley TR, 3rd, Smith JP. Ibuprofen-induced hepatotoxicity in patients with chronic hepatitis C: a case series. The American journal of gastroenterology 1998;93:1563-5. 24. Kang H, Choi JD, Jung IG, et al. A case of methimazole-induced acute hepatic failure in a patient with chronic hepatitis B carrier. The Korean journal of internal medicine 1990;5:69-73. 25. Pande JN, Singh SP, Khilnani GC, Khilnani S, Tandon RK. Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax 1996;51:132-6. 26. Dossing M, Wilcke JT, Askgaard DS, Nybo B. Liver injury during antituberculosis treatment: an 11-year study. Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 1996;77:335-40. 27. Cross FS, Long MW, Banner AS, Snider DE, Jr. Rifampin-isoniazid therapy of alcoholic and nonalcoholic tuberculous patients in a U.S. Public Health Service Cooperative Therapy Trial. The American review of respiratory disease 1980;122:349-53. 28. Whiting-O'Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta-analysis. The American journal of medicine 1991;90:711-6. 29. Malatjalian DA, Ross JB, Williams CN, Colwell SJ, Eastwood BJ. Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up. Canadian journal of gastroenterology = Journal canadien de gastroenterologie 1996;10:369-75. 30. MacDonald JS, Gerson RJ, Kornbrust DJ, et al. Preclinical evaluation of lovastatin. The American journal of cardiology 1988;62:16J-27J. 31. Horsmans Y, Desager JP, Harvengt C. Biochemical changes and morphological alterations of the liver in guinea-pigs after administration of simvastatin (HMG CoA reductase-inhibitor). Pharmacology & toxicology 1990;67:336-9. 32. Tolman KG. The liver and lovastatin. The American journal of cardiology 2002;89:1374-80. 33. de Denus S, Spinler SA, Miller K, Peterson AM. Statins and liver toxicity: a meta-analysis. Pharmacotherapy 2004;24:584-91. 34. Kashani A, Phillips CO, Foody JM, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 2006;114:2788-97. 35. Tolman KG. Defining patient risks from expanded preventive therapies. The American journal of cardiology 2000;85:15E-9E. 36. Russo MW, Scobey M, Bonkovsky HL. Drug-induced liver injury associated with statins. Semin Liver Dis 2009;29:412-22. 37. Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008;135:1924-34, 34 e1-4. 38. Motola D, Vargiu A, Leone R, et al. Hepatic adverse drug reactions: a case/non-case study in Italy. European journal of clinical pharmacology 2007;63:73-9. 39. Bjornsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. Journal of hepatology 2012;56:374-80. 40. Nseir W, Shalata A, Marmor A, Assy N. Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease. Digestive diseases and sciences 2011;56:3439-49. 41. Shalev V, Chodick G, Silber H, Kokia E, Jan J, Heymann AD. Continuation of statin treatment and all-cause mortality: a population-based cohort study. Archives of internal medicine 2009;169:260-8. 42. Tzefos M, Olin JL. 3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitor use in chronic liver disease: a therapeutic controversy. Journal of clinical lipidology 2011;5:450-9. 43. Ekstedt M, Franzen LE, Mathiesen UL, Holmqvist M, Bodemar G, Kechagias S. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. Journal of hepatology 2007;47:135-41. 44. Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010;376:1916-22. 45. Guiltinan AM, Kaidarova Z, Custer B, et al. Increased all-cause, liver, and cardiac mortality among hepatitis C virus-seropositive blood donors. American journal of epidemiology 2008;167:743-50. 46. Khorashadi S, Hasson NK, Cheung RC. Incidence of statin hepatotoxicity in patients with hepatitis C. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2006;4:902-7; quiz 806. 47. Segarra-Newnham M, Parra D, Martin-Cooper EM. Effectiveness and hepatotoxicity of statins in men seropositive for hepatitis C virus. Pharmacotherapy 2007;27:845-51. 48. Lewis JH, Mortensen ME, Zweig S, Fusco MJ, Medoff JR, Belder R. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 2007;46:1453-63. 49. Abraldes JG, Albillos A, Banares R, et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 2009;136:1651-8. 50. Abu Rajab M, Kaplan MM. Statins in primary biliary cirrhosis: are they safe? Digestive diseases and sciences 2010;55:2086-8. 51. Danan G, Benichou C. Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. Journal of clinical epidemiology 1993;46:1323-30. 52. Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs--II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. Journal of clinical epidemiology 1993;46:1331-6. 53. Jinjuvadia K, Kwan W, Fontana RJ. Searching for a needle in a haystack: use of ICD-9-CM codes in drug-induced liver injury. The American journal of gastroenterology 2007;102:2437-43. 54. Wolters LM, Van Buuren HR. Rosuvastatin-associated hepatitis with autoimmune features. European journal of gastroenterology & hepatology 2005;17:589-90. 55. Famularo G, Miele L, Minisola G, Grieco A. Liver toxicity of rosuvastatin therapy. World journal of gastroenterology : WJG 2007;13:1286-8. 56. Oteri A, Catania MA, Russo A, et al. Reversible acute hepatitis induced by rosuvastatin. Southern medical journal 2008;101:768. 57. Kato JD, Wang CT. Cardiac rehabilitation participant with sickle cell trait and statin-related hepatotoxicity: a case report. Journal of cardiopulmonary rehabilitation and prevention 2012;32:182-6. 58. Group TLS. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet 2002;359:1379-87. 59. Jukema JW, Cannon CP, de Craen AJ, Westendorp RG, Trompet S. The controversies of statin therapy: weighing the evidence. Journal of the American College of Cardiology 2012;60:875-81. 60. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA : the journal of the American Medical Association 2005;294:2437-45. 61. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. The New England journal of medicine 2004;350:1495-504. 62. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. The New England journal of medicine 2005;352:1425-35. 63. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA : the journal of the American Medical Association 2006;295:1556-65. 64. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ (Clinical research ed) 2010;340:c2197. 65. Koga T, Shimada Y, Kuroda M, Tsujita Y, Hasegawa K, Yamazaki M. Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Biochimica et biophysica acta 1990;1045:115-20. 66. Buckett L, Ballard P, Davidson R, et al. Selectivity of ZD4522 for inhibition of cholesterol synthesis in hepatic versus non-hepatic cells. Atherosclerosis 2000;151:41. 67. Nezasa K, Higaki K, Hasegawa H, et al. Uptake of HMG-CoA reductase inhibitor ZD4522 into hepatocytes and distribution into liver and other tissues of the rat. Atherosclerosis 2000;151:39. 68. Nezasa K, Higaki K, Matsumura T, et al. Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin. Drug metabolism and disposition: the biological fate of chemicals 2002;30:1158-63. 69. Kitamura S, Maeda K, Wang Y, Sugiyama Y. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug metabolism and disposition: the biological fate of chemicals 2008;36:2014-23. 70. Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clinical pharmacology and therapeutics 2007;82:726-33. 71. Iusuf D, van Esch A, Hobbs M, et al. Murine Oatp1a/1b uptake transporters control rosuvastatin systemic exposure without affecting its apparent liver exposure. Molecular pharmacology 2013;83:919-29. 72. Zhang W, Yu BN, He YJ, et al. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clinica chimica acta; international journal of clinical chemistry 2006;373:99-103. 73. Zamber CP, Lamba JK, Yasuda K, et al. Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics 2003;13:19-28. 74. Lee E, Ryan S, Birmingham B, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clinical pharmacology and therapeutics 2005;78:330-41. 75. Tomita Y, Maeda K, Sugiyama Y. Ethnic Variability in the Plasma Exposures of OATP1B1 Substrates Such as HMG-CoA Reductase Inhibitors: A Kinetic Consideration of Its Mechanism. Clinical pharmacology and therapeutics 2013;94:37-51. 76. Ucar M, Mjorndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug safety : an international journal of medical toxicology and drug experience 2000;22:441-57. 77. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA : the journal of the American Medical Association 2004;292:2585-90. 78. Rosenson RS. Current overview of statin-induced myopathy. The American journal of medicine 2004;116:408-16. 79. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clinical pharmacology and therapeutics 2006;80:565-81. 80. Alsheikh-Ali AA, Ambrose MS, Kuvin JT, Karas RH. The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation 2005;111:3051-7. 81. Garcia-Rodriguez LA, Gonzalez-Perez A, Stang MR, Wallander MA, Johansson S. The safety of rosuvastatin in comparison with other statins in over 25,000 statin users in the Saskatchewan Health Databases. Pharmacoepidemiology and drug safety 2008;17:953-61. 82. Garcia-Rodriguez LA, Masso-Gonzalez EL, Wallander MA, Johansson S. The safety of rosuvastatin in comparison with other statins in over 100,000 statin users in UK primary care. Pharmacoepidemiology and drug safety 2008;17:943-52. 83. McAfee AT, Ming EE, Seeger JD, et al. The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48,000 initiators of statin therapy. Pharmacoepidemiology and drug safety 2006;15:444-53. 84. Goettsch WG, Heintjes EM, Kastelein JJ, Rabelink TJ, Johansson S, Herings RM. Results from a rosuvastatin historical cohort study in more than 45,000 Dutch statin users, a PHARMO study. Pharmacoepidemiology and drug safety 2006;15:435-43. 85. Garcia Rodriguez LA, Herings R, Johansson S. Use of multiple international healthcare databases for the detection of rare drug-associated outcomes: a pharmacoepidemiological programme comparing rosuvastatin with other marketed statins. Pharmacoepidemiology and drug safety 2010;19:1218-24. 86. Kasliwal R, Wilton LV, Cornelius V, Aurich-Barrera B, Shakir SA. Safety profile of rosuvastatin: results of a prescription-event monitoring study of 11,680 patients. Drug safety : an international journal of medical toxicology and drug experience 2007;30:157-70. 87. Avins AL, Manos MM, Ackerson L, et al. Hepatic effects of lovastatin exposure in patients with liver disease: a retrospective cohort study. Drug safety : an international journal of medical toxicology and drug experience 2008;31:325-34. 88. Minakata Y, Ueda H, Akamatsu K, et al. High COPD prevalence in patients with liver disease. Internal medicine (Tokyo, Japan) 2010;49:2687-91. 89. Stoller JK, Aboussouan LS. Alpha1-antitrypsin deficiency. Lancet 2005;365:2225-36. 90. Zhu YJ. Epidemiological survey of chronic obstructive pulmonary disease and alpha-1-deficiency in China. Respirology (Carlton, Vic) 2001;6 Suppl:S13-5. 91. Seyama K. State of alpha1-antitrypsin deficiency in Japan. Respirology (Carlton, Vic) 2001;6 Suppl:S35-8. 92. de Serres FJ, Blanco I, Fernandez-Bustillo E. Estimated numbers and prevalence of PI*S and PI*Z deficiency alleles of alpha1-antitrypsin deficiency in Asia. The European respiratory journal 2006;28:1091-9. 93. Ebert EC. Hypoxic liver injury. Mayo Clinic proceedings Mayo Clinic 2006;81:1232-6. 94. Henrion J, Minette P, Colin L, Schapira M, Delannoy A, Heller FR. Hypoxic hepatitis caused by acute exacerbation of chronic respiratory failure: a case-controlled, hemodynamic study of 17 consecutive cases. Hepatology 1999;29:427-33. 95. Henrion J, Colin L, Schapira M, Heller FR. Hypoxic hepatitis caused by severe hypoxemia from obstructive sleep apnea. Journal of clinical gastroenterology 1997;24:245-9. 96. Mathurin P, Durand F, Ganne N, et al. Ischemic hepatitis due to obstructive sleep apnea. Gastroenterology 1995;109:1682-4. 97. Lane K, Dixon JJ, Macphee IA, Philips BJ. Renohepatic crosstalk: does acute kidney injury cause liver dysfunction? Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2013. 98. 郭旭崧, 施文儀, 林頂, et al. 台灣結核病防治年報. 行政院衛生局疾病管制局 2007. 99. 張峰義, 施文儀, 周志浩, et al. 台灣結核病防治年報. 行政院衛生局疾病管制局 2012. 100. Metushi IG, Cai P, Zhu X, Nakagawa T, Uetrecht JP. A fresh look at the mechanism of isoniazid-induced hepatotoxicity. Clinical pharmacology and therapeutics 2011;89:911-4. 101. Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest 1991;99:465-71. 102. Davidson DG, Eastham WN. Acute liver necrosis following overdose of paracetamol. British medical journal 1966;2:497-9. 103. Dargan PI, Jones AL. Management of paracetamol poisoning. Trends in pharmacological sciences 2003;24:154-7. 104. Wang K, Huang YS, Deng JF, et al. Characteristics and risk factors of acetaminophen-induced hepatitis in Taiwan. Zhonghua yi xue za zhi = Chinese medical journal; Free China ed 1999;62:369-75. 105. Tsai CL, Chang WT, Weng TI, Fang CC, Chen WJ. Acute acetaminophen intoxication in Taiwan: outcomes and risk factors. Journal of the Formosan Medical Association = Taiwan yi zhi 2004;103:830-5. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/17260 | - |
dc.description.abstract | 研究背景:Statins是目前最廣泛使用在降血脂的藥品,其在上市初期即被關注其可能的肝毒性,但一直以來都缺乏有系統的研究來支持其與肝毒性的相關性。在台灣藥物不良反應通報系統的案例分析中,statins造成的肝損傷有相當高的通報數,此與目前已發表的文獻有所差異。
研究目的:利用台灣健保資料庫來探討statins與肝損傷的相關性,並進一步探討statins之使用狀況與病人的特性是否為肝損傷的風險因子之一。 研究材料與方法 本研究為一病例對照研究,利用健保資料庫2000、2005、2010之百萬承保歸人檔為研究材料(涵蓋人口約300萬人)。研究族群為2001年至2009年間年齡大於等於20歲,並排除進入cohort前被診斷過病毒性肝炎與慢性肝病以外的肝病或資料不全的病人。病例為2002年至2009年間曾因肝損傷而住院的病人,而非因肝損傷住院的病人作為控制組,並藉由性別、年齡與index date作為配對標準,進行1:4的配對。資料分析利用mutivariable conditional logistic regression進行odd ratio的預測並校正干擾因子,也利用分層分析的方式來檢視可能的干擾。 研究結果:在研究期間內收錄研究族群共2,230,087人,排除18449人,最後共2,211,638人進入此研究。得病例共4166人,配對後病例組與對照組共4165人與16660人。結果顯示整體使用statins與肝損傷的相關性並不顯著(adjusted odd ratio(aOR) 1.04; 95% CI [0.90-1.19]),累積暴露≥120天(aOR 1.07; 95% CI [0.91-1.27])與累積劑量≥120 DDD(aOR 1.14; 95% CI [0.95-1.37])亦無顯著相關,而statin事件前劑量大於等於1 DDD(aOR 1.55; 95% CI [1.14-2.11])與事件前使用rosuvastatin(aOR 1.38; 95% CI [1.03-1.85])有統計上顯著相關。在分層分析中,以病人是否患有肝病來分析,在無肝病的族群中仍存在事件前劑量≥1 DDD與肝損傷的相關性有統計上的顯著(aOR 1.81; 95% CI [1.22-2.67]),但在有患病的病人則沒有看到此一現象。 結論:本研究並未發現整體使用statins與肝損傷的相關性,僅有使用rosuvastatin與statins劑量大於等於1 DDD時可能增加肝損傷的風險,並且有肝病的病人並不會增加statins造成肝損傷的風險。 | zh_TW |
dc.description.abstract | Background: Statins are widely used in the treatment of hyperlipidemia in the world. When they were launched into the market, they have been concerned about the side effects of hepatotoxicity. However, there is a lack of systemic studies to support the statin-associated liver injury. Statins were reported with number of cases with liver injury in Taiwan adverse drug reaction (ADR) reporting system. The data conflict with the current concept, rare statin-induced liver injury.
Objective: Using Taiwan's National Health Insurance Research Database (NHIRD), the aim of this study was to evaluate the association between statin use and liver injury in Taiwanese. Materials and Methods: This is a case-control study using 2000, 2005, 2010 Longitudinal Health Insurance Database(LHID) as study materials (covering about a population of 3 millions). The study population was defined as patients’ age ≥ 20 years old between 2001 and 2009. The exclusion criteria were patients who were diagnosed of liver diseases before the cohort entry date and patients whose data were incomplete. The cases were patients who were admitted with a primary diagnosis of liver injury between 2002 and 2009, and the controls were patients who were admitted without liver injury. The cases were matched with 4 controls by age, sex and the index date. Multivariable conditional regression models were used to estimate odds of liver injury associated with statin use. Furthermore, we conduct stratified analyses to assess the impact of the history of liver diseases on this potential association. Results: In the study period, 2,230,087 patients met the inclusion criteria. After excluding 18,449 patients, 2,211,638 patients served as the study population and 4,166 patients were the cases. After matching, 4,165 and 16,660 patients were the case and the controls, respectively. Overall, users of statins were not associated with risk of liver injury (adjusted odds ratio (aOR) 1.04; 95% confidence interval (CI) [0.90-1.19]) as compared to non-users. Increased cumulative duration (aOR 1.07; 95% CI [0.91-1.27]) and dose (OR 1.14; 95% CI [0.95-2.11]) of statins were not associated with risk of liver injury. Nevertheless, a higher dose of statin (≥ 1 defined daily dose (DDD) (aOR 1.55; 95% CI [1.14-2.11]) and use of rosuvastatin before event of liver injury (aOR 1.38; 95% CI [1.03-1.85]) were significantly associated with liver injury. In the startifed analyses, patients without liver disease still had significant association with statin’s dose before event ≥ 1 DDD and liver injury (aOR 1.81; 95% CI [1.22-2.67]). However, we do not see this situation in patients with liver diseases. Conclusions: This population-based study extends previous evidence by exploring the potential association between statins use and risk of liver injury. Liver diseases are not associated with increased risk of statin-induced liver injury in patients. However, our findings suggest that only the dose of statin ≥ 1 DDD and the use of rosuvastion may increase the risk of liver injury. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T00:03:36Z (GMT). No. of bitstreams: 1 ntu-102-R00451008-1.pdf: 995884 bytes, checksum: df48506511df8b983f7a04b6759fea4d (MD5) Previous issue date: 2013 | en |
dc.description.tableofcontents | 致謝 i
中文摘要 iii Abstract v 目錄 vii 表目錄 x 圖目錄 xii 第1章前言 1 第2章文獻回顧 2 2.1 藥品引起的肝損傷之文獻回顧 2 2.1.1 藥品引起的肝損傷之定義 2 2.1.2發生率與可疑藥品 3 2.1.3藥品引起的肝損傷之風險因子 3 2.2降血脂藥品Statins與藥品引起的肝損傷之關係 5 2.2.1 降血脂藥品Statins與藥品引起的肝損傷的研究文獻 5 2.2.2 降血脂藥品Statins與慢性肝病 7 2.3藥品引起的肝損傷之評估與資料庫編碼 8 2.3.1藥品引起的肝損傷的關係評估 8 2.3.2 藥品引起的肝損傷之資料庫編碼確效 9 第3章研究目的 10 3.1 研究動機 10 3.2 研究目的 10 第4章研究方法 11 4.1研究設計 11 4.2 資料來源 11 4.2.1臺灣全民健康保險研究資料庫 11 4.2.2 承保抽樣歸人檔 11 4.3 研究對象 12 4.3.1 病人族群 12 4.3.2病例組定義 12 4.3.3對照組定義 13 4.4 Statins之暴露變項 13 4.4.1 Statins使用資料 13 4.4.2 Statin使用狀況之定義 13 4.4.3 Statins之用藥時間與劑量 14 4.5病人資料蒐集 14 4.5.1 病人基本資料 14 4.5.2 共病史 14 4.5.3 肝病史 15 4.5.4 其他可能引起肝損傷的藥物 15 4.5.5 藥物交互作用 15 4.6統計分析 16 4.6.1 作業軟體 16 4.6.2 統計模型設定 16 4.6.3 回歸模型 16 第5章研究結果 17 5.1病人的基本特性分析 17 5.1.1 納入病人人數 17 5.1.2 病人基本特性 17 5.2病例組與對照組statins的使用分析 18 5.2.1 整體statins的使用分析 18 5.2.2 不同statin的使用分析 19 5.3降血脂藥品Statins與肝損傷的風險相關性 19 5.3.1 Statins之使用狀況與肝損傷之相關性 19 5.3.2 Statins累積暴露、累積劑量、事件前劑量、藥品交互作用與肝損傷之相關性 20 5.3.3不同statin與肝損傷之相關性 20 5.4 建立肝損傷與其風險因子之統計模型 21 5.5以肝病分層分析statins與肝損傷之相關性 21 5.5.1 以肝病分層 21 5.5.2 以病毒性肝炎分層 21 5.5.3 以慢性肝病分層 22 第6章討論 23 6.1研究族群之特性與藥品之使用 23 6.2 降血脂藥品statins與肝損傷之相關性 23 6.2.1 Statins的使用狀況與肝損傷之相關性 23 6.2.2 Statins的累積暴露、累積劑量和事件前劑量與肝損傷之相關性 24 6.2.3 Rosuvastatin與肝損傷之相關性 25 6.2.4 Statin與肝病對於肝損傷的影響 27 6.3 肝損傷之風險因子 27 6.4研究特點與其限制 29 6.4.1 本研究之特色與優點 29 6.4.2 研究限制 30 第7章結論 31 表 32 圖 54 參考文獻 55 | |
dc.language.iso | zh-TW | |
dc.title | 降血脂藥品statins與肝損傷風險:病例對照研究 | zh_TW |
dc.title | Statins and the Risk of Liver Injury: A Population-based Case-control Study | en |
dc.type | Thesis | |
dc.date.schoolyear | 101-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 蕭斐元(Fei-Yuan Sharon Hsiao) | |
dc.contributor.oralexamcommittee | 張家勳,林慧玲 | |
dc.subject.keyword | Statin,肝損傷,全民健保資料庫,病例對照研究, | zh_TW |
dc.subject.keyword | statin,liver injury,National Health Insurance Research Database (NHIRD),case-control study, | en |
dc.relation.page | 63 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2013-08-14 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床藥學研究所 | zh_TW |
顯示於系所單位: | 臨床藥學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-102-1.pdf 目前未授權公開取用 | 972.54 kB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。